SG10201900605SA - Humanized monoclonal antibody for inhibiting vascular endothelial lipase enzyme activity - Google Patents
Humanized monoclonal antibody for inhibiting vascular endothelial lipase enzyme activityInfo
- Publication number
- SG10201900605SA SG10201900605SA SG10201900605SA SG10201900605SA SG10201900605SA SG 10201900605S A SG10201900605S A SG 10201900605SA SG 10201900605S A SG10201900605S A SG 10201900605SA SG 10201900605S A SG10201900605S A SG 10201900605SA SG 10201900605S A SG10201900605S A SG 10201900605SA
- Authority
- SG
- Singapore
- Prior art keywords
- monoclonal antibody
- vascular endothelial
- humanized monoclonal
- endothelial lipase
- enzyme activity
- Prior art date
Links
- 102100031375 Endothelial lipase Human genes 0.000 title abstract 3
- 101710087274 Endothelial lipase Proteins 0.000 title abstract 3
- 230000002792 vascular Effects 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014184710 | 2014-09-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201900605SA true SG10201900605SA (en) | 2019-02-27 |
Family
ID=55459146
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201900605SA SG10201900605SA (en) | 2014-09-11 | 2015-09-10 | Humanized monoclonal antibody for inhibiting vascular endothelial lipase enzyme activity |
| SG11201701762VA SG11201701762VA (en) | 2014-09-11 | 2015-09-10 | Humanized monoclonal antibody for inhibiting vascular endothelial lipase enzyme activity |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201701762VA SG11201701762VA (en) | 2014-09-11 | 2015-09-10 | Humanized monoclonal antibody for inhibiting vascular endothelial lipase enzyme activity |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10570215B2 (fr) |
| EP (1) | EP3192813A4 (fr) |
| JP (2) | JP6635599B2 (fr) |
| KR (1) | KR102520286B1 (fr) |
| CN (1) | CN107074963B (fr) |
| AR (1) | AR101811A1 (fr) |
| AU (1) | AU2015313179B2 (fr) |
| BR (1) | BR112017004429A2 (fr) |
| CA (1) | CA2960994A1 (fr) |
| CL (1) | CL2017000595A1 (fr) |
| EA (1) | EA036324B1 (fr) |
| IL (1) | IL250981B (fr) |
| MX (1) | MX2017002968A (fr) |
| MY (1) | MY181835A (fr) |
| PH (1) | PH12017500461A1 (fr) |
| SG (2) | SG10201900605SA (fr) |
| TW (2) | TWI688575B (fr) |
| WO (1) | WO2016039402A1 (fr) |
| ZA (1) | ZA201702489B (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11351269B2 (en) * | 2015-06-30 | 2022-06-07 | Seagen Inc. | Anti-NTB-A antibodies and related compositions and methods |
| US11623954B2 (en) * | 2017-07-10 | 2023-04-11 | Innate Pharma | Siglec-9-neutralizing antibodies |
| EP3712170A4 (fr) * | 2017-11-10 | 2022-03-02 | Jiangsu Hengrui Medicine Co., Ltd. | Anticorps cd96, fragment de liaison à l'antigène de celui-ci et utilisation pharmaceutique associée |
| CA3192235A1 (fr) * | 2019-11-07 | 2021-05-14 | Medimmune, Llc | Anticorps de lipase endotheliale pour le traitement de maladies cardiovasculaires |
| CA3211692A1 (fr) * | 2020-02-24 | 2023-09-02 | Medimmune, Llc | Formulations d'anticorps anti-lipase endotheliale |
| WO2022095934A1 (fr) * | 2020-11-05 | 2022-05-12 | 上海津曼特生物科技有限公司 | Anticorps anti-siglec-15 et son utilisation dans la préparation d'un médicament |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH062075B2 (ja) * | 1988-04-30 | 1994-01-12 | 大日本製薬株式会社 | 抗ヒトポストヘパリンプラズマ由来リポ蛋白リパーゼモノクローナル抗体およびその製造方法 |
| IL129986A0 (en) * | 1996-12-06 | 2000-02-29 | Rhone Poulenc Rorer Pharma | Polypeptides encoded by a human lipase-like gene compositions and methods |
| WO1999032611A1 (fr) | 1997-12-19 | 1999-07-01 | Progenitor, Inc. | Lipase exprimee dans des cellules endotheliales et procedes d'utilisation associes |
| CA2363486C (fr) | 1999-03-26 | 2012-12-18 | Michael Jaye | Compositions et procedes agissant sur les taux de cholesterol des lipoproteines de haute densite (hdl) et des apolipoproteines ai, sur les taux de cholesterol des lipoproteines detres faible densite (vldl) et sur le taux de cholesterol des lipoproteines de faible densite (ldl) |
| JP6195306B2 (ja) * | 2011-10-12 | 2017-09-13 | 塩野義製薬株式会社 | Ｅｌの酵素活性を阻害するｅｌに対するモノクローナル抗体 |
| JP6304775B2 (ja) * | 2013-03-14 | 2018-04-04 | 塩野義製薬株式会社 | 血管内皮リパーゼの酵素活性を阻害するモノクローナル抗体 |
-
2015
- 2015-09-07 TW TW104129560A patent/TWI688575B/zh active
- 2015-09-07 TW TW109108293A patent/TWI734410B/zh active
- 2015-09-10 AU AU2015313179A patent/AU2015313179B2/en active Active
- 2015-09-10 EP EP15840346.9A patent/EP3192813A4/fr not_active Withdrawn
- 2015-09-10 KR KR1020177009620A patent/KR102520286B1/ko active IP Right Grant
- 2015-09-10 AR ARP150102894A patent/AR101811A1/es unknown
- 2015-09-10 MX MX2017002968A patent/MX2017002968A/es unknown
- 2015-09-10 JP JP2016547492A patent/JP6635599B2/ja active Active
- 2015-09-10 WO PCT/JP2015/075668 patent/WO2016039402A1/fr active Application Filing
- 2015-09-10 CA CA2960994A patent/CA2960994A1/fr active Pending
- 2015-09-10 SG SG10201900605SA patent/SG10201900605SA/en unknown
- 2015-09-10 SG SG11201701762VA patent/SG11201701762VA/en unknown
- 2015-09-10 EA EA201790590A patent/EA036324B1/ru not_active IP Right Cessation
- 2015-09-10 CN CN201580059706.8A patent/CN107074963B/zh active Active
- 2015-09-10 BR BR112017004429-3A patent/BR112017004429A2/pt active Search and Examination
- 2015-09-10 MY MYPI2017700661A patent/MY181835A/en unknown
-
2017
- 2017-03-07 IL IL250981A patent/IL250981B/en active IP Right Grant
- 2017-03-10 PH PH12017500461A patent/PH12017500461A1/en unknown
- 2017-03-10 CL CL2017000595A patent/CL2017000595A1/es unknown
- 2017-03-10 US US15/456,041 patent/US10570215B2/en active Active
- 2017-04-07 ZA ZA2017/02489A patent/ZA201702489B/en unknown
-
2019
- 2019-11-18 US US16/687,272 patent/US11136411B2/en active Active
- 2019-12-16 JP JP2019226429A patent/JP6827255B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201900605SA (en) | Humanized monoclonal antibody for inhibiting vascular endothelial lipase enzyme activity | |
| PH12020500240A1 (en) | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies | |
| MX2017001976A (es) | Terapia de combinacion de anticuerpos activadores de la cd40 humana y anticuerpos contra el mp-l1 humano. | |
| WO2015123423A3 (fr) | Méthodes de traitement de patients atteints d'hypercholestérolémie non correctement maîtrisée par une thérapie à la statine à dose modérée | |
| EA201200559A1 (ru) | Способы назначения терапии пирфенидоном | |
| PH12014501122A1 (en) | Methods of treatment using an antibody against interferon gamma | |
| MX338610B (es) | Composiciones farmaceuticas que comprenden sulbactam e inhibidor de beta-lactamasa. | |
| WO2012125544A3 (fr) | Inhibiteurs de la nécroptose et leurs méthodes d'utilisation | |
| MA47362A (fr) | Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif | |
| PH12018501646A1 (en) | Compositions and methods for treating infections | |
| MY193996A (en) | Tripeptide compound, preparation method therefor, and application thereof | |
| EA201600012A1 (ru) | Способ профилактики и/или лечения сердечно-сосудистых заболеваний | |
| PH12015502092A1 (en) | Monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase | |
| AU2018258588A8 (en) | Inhibitors of TRIM33 and methods of use | |
| MX2018000571A (es) | Procedimiento para el aclareo de frutas. | |
| ZA202005083B (en) | Solid forms of fasoracetam | |
| EP3783022A3 (fr) | Anticorps anti-vegf-a et leurs utilisations | |
| MX2019014773A (es) | Inhibidores de ccl2. | |
| EP4006163A4 (fr) | Enzyme capable de déshydroxyler un groupe hydroxyle dans un composé urolithine | |
| MX2018003453A (es) | Terapias conjuntas con inhibidores de produccion de glucosa. |